Kendall Capital Partners

EpiBone, Inc. is a biotechnology company based in Brooklyn, New York, that specializes in developing advanced bone and cartilage reconstruction solutions. Founded in 2013, EpiBone leverages innovative techniques involving patient-specific bone scans and the use of the patient's own stem cells to create autologous-like bone grafts. These grafts are cultivated in custom bioreactors, promoting efficient bone formation and regeneration. EpiBone's lead product, an anatomically precise living 3D bone graft, successfully completed its Phase I/IIa clinical trial in August 2023, while the company is also developing a cartilage repair portfolio that includes an allogeneic osteochondral plug and an injectable cartilage filler. This pioneering work positions EpiBone at the forefront of regenerative medicine, aiming to transform orthopedic repair and improve patient outcomes through a streamlined surgical approach and reduced recovery times.

Omnipulse Biosciences, based in Cambridge, Massachusetts, is a drug development company operating in stealth mode. It specializes in producing single injection quantities of pharmaceuticals, catering to the needs of clinical trials and facilitating access to low-income countries.

EpiBone, Inc. is a biotechnology company based in Brooklyn, New York, that specializes in developing advanced bone and cartilage reconstruction solutions. Founded in 2013, EpiBone leverages innovative techniques involving patient-specific bone scans and the use of the patient's own stem cells to create autologous-like bone grafts. These grafts are cultivated in custom bioreactors, promoting efficient bone formation and regeneration. EpiBone's lead product, an anatomically precise living 3D bone graft, successfully completed its Phase I/IIa clinical trial in August 2023, while the company is also developing a cartilage repair portfolio that includes an allogeneic osteochondral plug and an injectable cartilage filler. This pioneering work positions EpiBone at the forefront of regenerative medicine, aiming to transform orthopedic repair and improve patient outcomes through a streamlined surgical approach and reduced recovery times.

Eyenuk, Inc. is a medtech company that specializes in artificial intelligence-based retinal image analysis and disease detection technology. Founded in 2010 and headquartered in Woodland Hills, California, Eyenuk develops innovative solutions aimed at enhancing the screening process for various eye diseases. Its flagship product, the EyeArt AI Eye Screening System, is recognized for its autonomous detection of diabetic retinopathy, requiring no expert human grading or eye dilation. The company also offers EyeMark, which monitors retinopathy progression, and EyeApp, a mobile application facilitating diabetic retinopathy screening via smartphones. Additionally, Eyenuk provides EyeSeeAMD, a technology designed to identify age-related macular degeneration. Through its advanced solutions, Eyenuk aims to ensure timely diagnosis of life- and vision-threatening conditions, including glaucoma and cardiovascular risks, ultimately striving to screen every eye globally.

Bilayer Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. The company focuses on developing innovative therapies using bile acids to address various diseases of the colon, including chronic idiopathic constipation, irritable bowel syndrome with constipation, inflammatory bowel disease, ulcerative colitis, Crohn's disease, type 2 diabetes, obesity, and metabolic disorders. Bilayer's technology aims to activate the body's natural mechanisms for regulating constipation, offering potential first-in-class treatment options for these prevalent health issues.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, that focuses on developing gene therapies to enhance health and extend the lifespans of dogs and other domesticated animals. Founded in 2017, the company utilizes innovative approaches derived from research at the Wyss Institute at Harvard Medical School to create anti-aging therapies and address age-related diseases. By introducing new DNA instructions into the bodies of pets, Rejuvenate Bio aims to offer solutions for chronic conditions and improve overall well-being. The company's gene therapy pipeline is designed to target specific diseases and leverage clinically validated gene targets to ensure effective and lasting results.